BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:GV20-0251 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of GV20-0251\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05669430-2037@assetmemo.bio
DTSTAMP:20261121T005728Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:GV20-0251: Phase 1/2 readout est. (NCT05669430)
DESCRIPTION:GV20-0251\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizu
 mab in Participants With Solid Tumor Malignancies\nEstimated primary compl
 etion: 15 December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/gv20-0251#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05669430
URL:https://assetmemo.bio/drug/gv20-0251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07457281-2037@assetmemo.bio
DTSTAMP:20261121T005728Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:GV20-0251: Phase 1 readout est. (NCT07457281)
DESCRIPTION:GV20-0251\, phase 1.\nStudy: GV20-0251 and Sintilimab for Neoad
 juvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Si
 ngle-Arm Study\nEstimated primary completion: 1 April 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/gv20-0251#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07457281
URL:https://assetmemo.bio/drug/gv20-0251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07106827-2037@assetmemo.bio
DTSTAMP:20261121T005728Z
DTSTART;VALUE=DATE:20270611
DTEND;VALUE=DATE:20270612
SUMMARY:GV20-0251: Phase 1 readout est. (NCT07106827)
DESCRIPTION:GV20-0251\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy of GV20-0251 in Advanced or Refractory Solid Tumors\nEstimated primary 
 completion: 11 June 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/gv20-0251#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07106827
URL:https://assetmemo.bio/drug/gv20-0251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07070518-2037@assetmemo.bio
DTSTAMP:20261121T005728Z
DTSTART;VALUE=DATE:20270716
DTEND;VALUE=DATE:20270717
SUMMARY:GV20-0251: Phase 1/2 readout est. (NCT07070518)
DESCRIPTION:GV20-0251\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Stu
 dy of GV20-0251 in Participants With Solid Tumor Malignancies\nEstimated p
 rimary completion: 16 July 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/gv20-0251#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07070518
URL:https://assetmemo.bio/drug/gv20-0251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07623642-2037@assetmemo.bio
DTSTAMP:20261121T005728Z
DTSTART;VALUE=DATE:20280615
DTEND;VALUE=DATE:20280616
SUMMARY:GV20-0251: Phase 2 readout est. (NCT07623642)
DESCRIPTION:GV20-0251\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Pha
 se II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodi
 es in Patients With Unresectable\, Locally Advanced\, or Metastatic Solid 
 Tumors.\nEstimated primary completion: 15 June 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/gv20-0251#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07623642
URL:https://assetmemo.bio/drug/gv20-0251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07307053-2037@assetmemo.bio
DTSTAMP:20261121T005728Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:GV20-0251: Phase 1/2 readout est. (NCT07307053)
DESCRIPTION:GV20-0251\, phase 1/2.\nStudy: Rare Tumor Focused Platform Stud
 y of Innovative Therapies and Technologies (PLATFORM2)\nEstimated primary 
 completion: 31 January 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/gv20-0251#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07307053
URL:https://assetmemo.bio/drug/gv20-0251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
